Evidence map›Paper›PMID 37920506›Full record

ArticleHeliyon2023

Chitosan-Based metal-organic framework for Stabilization of β-glucosidase: Reusability and storage stability.

Mustafa Zeyadi, Yaaser Q Almulaiky

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. NiNanoscale advances · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mustafa ZeyadiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, P. O. Box 80200, Jeddah, 21589, Saudi Arabia.
Yaaser Q AlmulaikyDepartment of Chemistry, College of Science and Arts at Khulis, University of Jeddah, Jeddah 21921, Saudi Arabia.
King Abdulaziz University · SATaiz University · YE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzyme immobilization is a powerful tool for protecting enzymes from harsh reaction conditions and improving enzyme activity, stability, and reusability. In this study, metal organic frameworks (MIL-Fe composites) were synthesized via solvothermal reactions and then modified with chitosan (CS). β-Glucosidase was immobilized on the chitosan-metal organic framework (CS-MIL-Fe), and the resulting composites were characterized with various analytical techniques. The β-glucosidase immobilized on a CS-MIL-Fe composite had an immobilization yield of 85 % and a recovered activity of 74 %. The immobilized enzyme retained 81 % of its initial activity after ten successive cycles and preserved 69 % of its original activity after 30 days of storage at 4 °C. In contrast, the free enzyme had only preserved 32 % of its original activity after 30 days. Under various temperature and pH conditions, the immobilized enzyme showed greater stability than the free enzyme, and the optimal temperature and pH were 60 °C and 6.0 for the immobilized enzyme and 50 °C and 5.0 for the free enzyme. The kinetic parameters were also determined, with the Km values of 13.4 and 6.98 mM for the immobilized and free β-glucosidase, respectively, and Vmax values of 3.96 and 1.72 U/mL, respectively. Overall, these results demonstrate that the CS-MIL-Fe@β-glucosidase is a promising matrix showing high catalytic efficiency and enhanced stability.

Indexed as

ImmobilizationMetal-organic frameworksReusabilityStabilityβ-glucosidase

Identifiers

PMID37920506
PMCPMC10618774
OpenAlexW4387747718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.